IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Immunome, Inc. (IMNM) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | D+ (1.7) | D (1.3) | C- (2.1) | C+ (2.6) | C- (2.0) |
| 2026-11-05 | C+ (2.5) | D (1.5) | D (1.3) | C (2.2) | C+ (2.7) | C- (2.0) |
| 2026-10-29 | C+ (2.5) | D (1.5) | D (1.3) | C+ (2.5) | C+ (2.7) | C- (2.1) |
| 2026-10-22 | C+ (2.5) | D (1.4) | D (1.3) | C+ (2.8) | C+ (2.6) | C- (2.1) |
| 2026-10-15 | C+ (2.5) | D (1.5) | D (1.3) | C+ (2.7) | C+ (2.6) | C- (2.1) |